Results 51 to 60 of about 50,358 (293)
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma [PDF]
, 2017 Leiomyosarcoma is an aggressive soft tissue sarcoma with poor patient survival. The genetic changes of leiomyosarcoma remain to be discovered. In this study, we analyzed the genetic changes of 44 cancer-related genes by using next-generation sequencing ...
鄭永銘;李仁傑;蔡佳惠;章明珠;楊卿堯;張毓廷;廖肇裕 +1 more
core
Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma With SQSTM1::ALK Fusion
Diagnostic Cytopathology, EarlyView.ABSTRACT Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare and aggressive variant of inflammatory myofibroblastic tumor (IMT) characterized by epithelioid morphology, atypical features, ALK rearrangements, and early metastatic potential.
Havva Gokce Terzioglu +2 more
wiley +1 more source
A potential diagnostic biomarker: Proteasome LMP2/b1i-differential expression in human uterus neoplasm [PDF]
, 2012 Uterine leiomyosarcoma (ULMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine ULMS
Nobuo Yaegashi +5 more
core +1 more source
Leiomyosarcoma of the breast [PDF]
Journal of Surgical Case Reports, 2011 Leiomyosarcomas of the breast are rare tumors. Less than 16 such cases have been reported in the literature so far. We present a case of a 44 year female patient who was found to have primary leiomyosarcoma of the breast.
Oktay, Y, Fikret, A
openaire +2 more sources
Cancer, 2017 Immunotherapy has changed the therapeutic landscape in oncology. Advanced uterine leiomyosarcoma (ULMS) remains an incurable disease in most cases, and despite new drug approvals, improvements in overall survival have been modest at best.
E. Ben-Ami +17 more
semanticscholar +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Treatment of sarcoma includes high‐dose anthracyclines, which can cause cardiotoxicity. This study assesses the correlation of cardiac biomarkers and echocardiographic parameters on asymptomatic cardiotoxicity in sarcoma patients treated with anthracyclines.
Elissa A. S. Polomski +6 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Complication reporting in spinal tumor surgery remains inconsistently defined. We aimed to quantify the incidence, severity, and spectrum of early (≤ 30 days) postoperative adverse events (AEs) in spinal tumor surgery and to identify predictors of overall and serious complications using standardized severity grading.
Meltem Ivren +6 more
wiley +1 more source
American Journal of Surgical Pathology, 2019 Genetic alterations in uterine myxoid leiomyosarcoma are unknown. We investigate the clinicopathologic features of 19 uterine tumors previously diagnosed as myxoid leiomyosarcomas in which tumoral RNA was subjected to targeted RNA sequencing. PLAG1, BCOR,
J. Arias-Stella +11 more
semanticscholar +1 more source
A Rare Case of Pulmonary Leiomyosarcoma
Acta Medica Indonesiana, 2023 Leiomyosarcoma commonly occurs in the abdomen, retroperitoneum, large blood vessels, and uterus[1]. Cardiac leiomyosarcoma is a rare and highly aggressive sarcoma.
Jialin He +7 more
doaj +2 more sources